AI Article Synopsis

  • A phase 2b trial evaluated the effectiveness of ritlecitinib, a JAK3/TEC kinase inhibitor, in treating patients with active non-segmental vitiligo, comparing different dosages against a placebo over 24 weeks.
  • Active vitiligo lesions showed higher levels of inflammatory markers compared to stable lesions, and patients with more active lesions had elevated serum levels of specific biomarkers.
  • After 24 weeks, the 50 mg dose of ritlecitinib significantly reduced depigmentation and increased repigmentation in stable lesions, while also influencing immune response markers in both active and stable lesions.

Article Abstract

The efficacy of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, on active and stable lesions was evaluated in patients with active non-segmental vitiligo in a phase 2b trial (NCT03715829). Patients were randomized to placebo or daily ritlecitinib 50 mg (with or without 4-week 100-mg or 200-mg loading dose), 30 mg, or 10 mg for 24 weeks. Active lesions showed greater baseline expression of inflammatory/immune markers IFNG and CCL5, levels of CD103, and T-cell infiltrates than stable lesions. Patients with more active than stable vitiligo lesions showed higher baseline serum levels of CXCL9 and PD-L1, while patients with more stable than active lesions showed higher baseline serum levels of HO-1. At Week 24, ritlecitinib 50 mg significantly stabilized mean percent change from baseline in depigmentation extent in both active lesions and stable lesions vs. placebo-response, with stable lesions showing greater repigmentation. After 24 weeks of treatment, ritlecitinib 50 mg increased expression of melanocyte markers in stable lesions, while Th1/Th2-related and co-stimulatory molecules decreased significantly in both stable and active lesions. Serum from patients with more active than stable lesions showed decreased levels of ICOS and NK cell activation markers. These data, confirmed at transcription/protein levels, indicate that stable lesion repigmentation occurs early with ritlecitinib, while active lesions require stabilization of inflammation first. ClinicalTrials.gov: NCT03715829.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11258076PMC
http://dx.doi.org/10.1007/s00403-024-03182-yDOI Listing

Publication Analysis

Top Keywords

stable lesions
28
active lesions
24
lesions
14
active stable
12
patients active
12
ritlecitinib 50 mg
12
stable
11
active
10
jak3/tec family
8
family kinase
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!